TY - JOUR
T1 - Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
AU - Wijarnpreecha, Karn
AU - Aby, Elizabeth S.
AU - Ahmed, Aijaz
AU - Kim, Donghee
N1 - Publisher Copyright:
© 2021 by Korean Association for the Study of the Liver.
PY - 2021
Y1 - 2021
N2 - Nonalcoholic fatty liver disease (NAFLD) is a multisystemic disease and a rapidly growing cause of chronic liver disease in children and adults worldwide. Diagnosis and management of extrahepatic manifestations of NAFLD, including cardiovascular disease (CVD), type 2 diabetes mellitus, metabolic syndrome, chronic kidney disease, obstructive sleep apnea, polycystic ovarian syndrome, hypothyroidism, psoriasis, and extrahepatic malignancy are crucial for the treatment of patients with NAFLD. The leading cause of death in NAFLD is primarily from CVD, followed by liver-related mortality, extrahepatic cancer, liver cancer, and diabetes-related mortality. Therefore, clinicians need to identify high-risk patients earlier in the disease course and be aware of the extrahepatic manifestations of NAFLD to improve liver disease outcomes. In this review, we focus on the monitoring and management of the extrahepatic manifestations of NAFLD.
AB - Nonalcoholic fatty liver disease (NAFLD) is a multisystemic disease and a rapidly growing cause of chronic liver disease in children and adults worldwide. Diagnosis and management of extrahepatic manifestations of NAFLD, including cardiovascular disease (CVD), type 2 diabetes mellitus, metabolic syndrome, chronic kidney disease, obstructive sleep apnea, polycystic ovarian syndrome, hypothyroidism, psoriasis, and extrahepatic malignancy are crucial for the treatment of patients with NAFLD. The leading cause of death in NAFLD is primarily from CVD, followed by liver-related mortality, extrahepatic cancer, liver cancer, and diabetes-related mortality. Therefore, clinicians need to identify high-risk patients earlier in the disease course and be aware of the extrahepatic manifestations of NAFLD to improve liver disease outcomes. In this review, we focus on the monitoring and management of the extrahepatic manifestations of NAFLD.
KW - Cardiovascular diseases
KW - Fatty liver
KW - Liver cirrhosis
KW - Non-alcoholic fatty liver disease
KW - Therapeutics
UR - http://www.scopus.com/inward/record.url?scp=85104738565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104738565&partnerID=8YFLogxK
U2 - 10.3350/cmh.2020.0239
DO - 10.3350/cmh.2020.0239
M3 - Article
C2 - 33317243
AN - SCOPUS:85104738565
SN - 2287-2728
VL - 27
SP - 221
EP - 235
JO - Clinical and molecular hepatology
JF - Clinical and molecular hepatology
IS - 2
ER -